Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non-small Cell Lung Carcinoma
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo
The purpose of the study is to qualify, independently, tumor cell proliferation by 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) -Positron Emission Tomography , and cell death by Diffusion Weighted Imaging (DWI) -Magnetic Resonance…
- Trial name
- EVIDENCE (NCT02273271)
- Testing
- 18F-FLT-PET/CT and DWI-MRI
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a…
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Recurrent, Small Cell Lung Cancer Extensive Stage
- Trial name
- NCT03994744
- Testing
- PD-1 inhibitor, Metformin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hunan Cancer Hospital
Small Cell Lung Cancer
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
This is an expanded access program in the USA to enable eligible patients with previously treated small cell lung cancer to access lurbinectedin treatment prior to FDA approval. Sites must apply to participate in the program.
- Trial name
- NCT04291937
- Testing
- Lurbinectedin
- Sponsor
- Jazz Pharmaceuticals
Non-small-cell Lung Cancer
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
This trial will evaluate the efficacy and safety of docetaxel plus bevacizumab in patients with pretreated, advanced non small cell lung cancer (NSCLC).
- Trial name
- NCT00741195
- Testing
- Docetaxel, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Oncology Research Group
Non Small Cell Lung Cancer Metastatic
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with < 50% of tumor cells expressing…
- Trial name
- NCT03353675
- Testing
- TG4010, Chemotherapy, Nivolumab
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 44 people
- Sponsor
- Transgene
Solid Tumor, Adult, Soft Tissue Sarcoma
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of metastatic, advanced, or recurrent solid tumors.
- Conditions
- Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04165330
- Testing
- AL3818, Nivolumab Injection
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00976677
- Testing
- erlotinib hydrochloride, paclitaxel, carboplatin
- Where
- 108 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)
To examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a…
- Trial name
- NCT00509457
- Testing
- GV 1001 Telomerase peptide
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Non Small Cell Lung Cancer, Lung Cancer
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
The purpose of this study is to determine the safety and efficacy of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC who are…
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
- Trial name
- NCT04069936
- Testing
- MILs™ - NSCLC, nivolumab, tadalafil
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- WindMIL Therapeutics
Dysbiosis
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
Lung cancer is the leading cancer in France in terms of mortality. The prognosis of the disease is closely correlated with the diagnostic stage and the majority of patients are diagnosed at a metastatic stage.
- Trial name
- ICI (NCT07191171)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Strasbourg, France
Carcinoma, Non-Small-Cell Lung
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that…
- Trial name
- NCT00051571
- Testing
- SGN-15, Docetaxel
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Seagen Inc.
Limited Stage Small Cell Lung Cancer
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
A total of 66 patients were enrolled in this exploratory study and randomly assigned to cohort 1 and cohort 2, with 33 patients in each group.
- Trial name
- NCT06978153
- Testing
- benmelstobart combined with chemotherapy and anlotinib, benmelstobart combined with chemotherapy
- Volunteers
- 66 people
- Sponsor
- Tang-Du Hospital
Lung Neoplasms, Non-Small Cell Lung Cancer
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer
Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation.
- Trial name
- PTR-2 (NCT07738172)
- Testing
- Primary Tumor Resection, Osimertinib
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00039039
- Testing
- carboplatin, chemotherapy, cisplatin
- Where
- 37 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Non-Small Cell Lung Cancer
Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)
The purpose of this study is to find out what effects, good and/or bad, proton radiation at a higher tumor dose (and lower normal surrounding lung dose) combined with standard chemotherapy has on lung cancer.
- Trial name
- LU02 (NCT00881712)
- Testing
- PET positive nodal disease measuring 15 mm or greater, PET positive nodal disease measuring less than 15 mm, Patients considered resectable
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Multiple Myeloma, Lymphoma, Non-Hodgkin
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S.
- Conditions
- Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease
- Trial name
- NCT02682667
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
This pilot clinical trial studies how well bronchoscopy with bronchoalveolar lavage works in identifying biomarkers of response to immune checkpoint inhibitors in patients with non-small cell or small cell lung cancer.
- Trial name
- NCT02937402
- Testing
- Bronchoscopy with Bronchoalveolar Lavage, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-small Cell Lung Cancer
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality in men and women in Singapore.Chemotherapy and biologically targeted agents can extend survival only modestly for these patients; therefore…
- Trial name
- NCT00809237
- Testing
- Gefitinib, Hydroxychloroquine
- Where
- Singapore
- Volunteers
- 71 people
- Sponsor
- National University Hospital, Singapore
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Soft Tissue Sarcoma
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival.
- Trial name
- NCT03449901
- Testing
- pegylated arginine deiminase, Gemcitabine, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.